Wu, Geting
28  results:
Search for persons X
?
5

ALKBH1-8 and FTO: Potential Therapeutic Targets and Prognos..:

Wu, Geting ; Yan, Yuanliang ; Cai, Yuan...
Frontiers in Cell and Developmental Biology.  9 (2021)  - p. , 2021
 
?
6

microRNA‐30a attenuates TGF‐β1–induced activation of pulmon..:

Wu, Geting ; Xie, Bin ; Lu, Can...
Journal of Cellular and Molecular Medicine.  24 (2020)  6 - p. 3745-3750 , 2020
 
?
7

Sulforaphane: Expected to Become a Novel Antitumor Compound:

Wu, Geting ; Yan, Yuanliang ; Zhou, Yangying...
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics.  28 (2020)  4 - p. 439-446 , 2020
 
?
8

N6-methyladenosine RNA modification in cancer therapeutic r..:

Xu, Zhijie ; Peng, Bi ; Cai, Yuan...
Biochemical Pharmacology.  182 (2020)  - p. 114258 , 2020
 
?
10

Expression and clinical significance of CPS1 in glioblastom..:

Wu, Geting ; Yan, Yuanliang ; Zhou, Yangying...
Current Research in Translational Medicine.  67 (2019)  4 - p. 123-128 , 2019
 
?
 
?
12

ALKBH1-8 and FTO: Potential Therapeutic Targets and Prognos..:

Wu, Geting ; Yan, Yuanliang ; Cai, Yuan...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209387/.  , 2021
 
?
 
?
14

microRNA‐30a attenuates TGF‐β1–induced activation of pulmon..:

Wu, Geting ; Xie, Bin ; Lu, Can...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131934/.  , 2020
 
?
15

CFHR1 is a potentially downregulated gene in lung adenocarc..:

Wu, Geting ; Yan, Yuanliang ; Wang, Xiang...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755197/.  , 2019
 
1-15